SCHEMBL5879202

SCHEMBL5879202

COc1ccc2c(c1)[nH]c1c3c(=O)[nH]c(=O)c3c3c(=O)[nH]c(=O)c3c21

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 6/20 0.62
CCND1 P24385 6/20 0.62
CDK2 P24941 4/20 0.56
CCNE2 O96020 3/20 0.56
CCNE1 P24864 3/20 0.56
ROCK2 O75116 1/20 0.56
CAMK2B Q13554 1/20 0.56
CAMK2G Q13555 1/20 0.56
CAMK2D Q13557 1/20 0.56
CAMK2A Q9UQM7 1/20 0.56
CHEK1 O14757 1/20 0.54
KDM4E B2RXH2 4/20 0.54
ALDH1A1 P00352 3/20 0.51
HPGD P15428 3/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
HCRTR1 O43613 1/20 0.51
HTT P42858 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
PRKACA P17612 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5879238 0.88 PDGFRB (0.62) ROCK2CHEK1KDM4EALDH1A1HPGD
SCHEMBL21563913 0.82 CDK4 (0.63) CDK4CCND1CDK2CCNE2CCNE1
SCHEMBL5879256 0.79 CHEK1 (0.63) CDK4CCND1CDK2CCNE2CCNE1
SCHEMBL5879177 0.78 ALDH1A1 (0.56) CHEK1KDM4EALDH1A1HPGDMEN1
SCHEMBL5879262 0.76 CTSV (0.61) CDK4CCND1CDK2CCNE2CCNE1
SCHEMBL26608014 0.76 CDK4 (0.56) CDK4CCND1CDK2CCNE2CCNE1
SCHEMBL5879318 0.76 CHEK1 (0.59) CDK4CCND1CDK2CCNE2CCNE1
SCHEMBL6201746 0.76 CHEK1 (0.59) CDK4CCND1CDK2CCNE2CCNE1
SCHEMBL5879261 0.76 CHEK1 (0.59) CDK4CCND1CDK2CCNE2CCNE1
SCHEMBL31451502 0.74 CDK4 (0.54) CDK4CCND1CDK2CCNE2CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151108-B2 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATORIES SERVIER (FR) 2006-12-19 US disclosed
EP-1411057-B1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-04-27 EP disclosed
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATOIRES SERVIER (FR) 2004-04-22 US disclosed
EP-1411057-A1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2004-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents XDH, TOP2A, TOP1 CDK4 1989/4885CCND1 405/4885CDK2 1249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.